A single high dose of intravenous iron therapy has no significant effect on intact fibroblast growth factor 23 (FGF23) plasma levels for up to 7 days in normal and uraemic rats, new data indicate. These findings are of importance owing to the associations between increased mortality and FGF23 in patients with chronic kidney disease (CKD), who are often prescribed iron therapy.

Recommended tests for iron deficiency anaemia can be dramatically affected by factors such as infection and inflammation, a new article reports. Although more accurate tests are available, they are not currently widely utilised, indicating that a change in current diagnostic practice for patients with chronic kidney disease (CKD) may be necessary.

In this interesting randomised multicentre open-label trial, the authors explore the traditional and well-known intravenous iron complex, iron sucrose, administered as multiple infusions over two weeks versus ferric carboxymaltose, which can be administered in only two applications over one week, in a large group of patients with iron deficiency anaemia and non-dialysis dependent chronic kidney disease (NDD-CKD). They conclude that although both regimens are similar regarding primary composite safety endpoints, ferric carboxymaltose is more effective and may reduce healthcare costs.

Two clinical trials have reported positive top-line results for their respective therapies, ferric carboxymaltose and soluble ferric pyrophosphate, in patients with chronic kidney disease, according to recent press releases. Together, these trials demonstrate the central role of iron across the chronic kidney disease spectrum, with benefits of iron therapy reported in dialysis and non-dialysis-dependent patient populations.

Ferric carboxymaltose assessment in subjects with iron deficiency anaemia and non-dialysis-dependent CKD (the FIND-CKD study)

This article highlights the importance of the relationship between serum hepcidin and iron deposition in the brain of patients with HBV-related cirrhosis. The study is based on a group of HBV-related cirrhotic patients and age- and sex-matched healthy controls.  The evaluation of brain iron content was conducted by susceptibility weighted phase imaging technique.


Subscribe to RSS - Nephrology